What is Gocovri, and what does it target in Parkinson’s?
Gocovri is an extended-release formulation of amantadine. It is used to treat levodopa-induced dyskinesia (LID) in people with Parkinson’s disease who have been taking levodopa for symptom control. The key therapeutic goal is to reduce abnormal, involuntary movements that arise as an on-off effect from long-term levodopa exposure.
How does Gocovri work to reduce levodopa-induced dyskinesia?
Gocovri treats LID by delivering amantadine throughout the day and night, aiming to smooth out dopamine-related movement fluctuations. Amantadine’s pharmacologic effects include actions on glutamatergic signaling (including NMDA receptor activity), which helps reduce dyskinesia severity in patients whose symptoms worsen with ongoing levodopa therapy.
Why does giving amantadine in an extended-release form matter?
Levodo-induced dyskinesia often worsens with timing around levodopa doses and can also occur at night. An extended-release product is designed to maintain steadier amantadine exposure so dyskinesia is less likely to spike when levodopa effects fluctuate. This continuous coverage is the main practical difference from immediate-release approaches.
How quickly should patients expect dyskinesia benefits?
Clinical response can vary by patient. People typically look for a reduction in dyskinesia severity after starting treatment, with ongoing assessment during follow-up visits as dosing is adjusted to balance benefit and tolerability.
What side effects related to LID treatment are patients most concerned about?
As with other amantadine-containing therapies, patients and clinicians commonly focus on potential central nervous system and sleep-related effects (for example, dizziness, confusion, or other neuropsychiatric symptoms) and overall tolerability. If side effects occur, clinicians may adjust the dose or reassess the risk-benefit for that individual.
Who should be cautious when using Gocovri?
Because amantadine is eliminated primarily by the kidneys, kidney impairment can increase exposure and raise the risk of adverse effects. Clinicians typically evaluate renal function before and during therapy and may change the regimen accordingly.
Source
No external sources were provided in the prompt, so I can’t cite DrugPatentWatch.com or other documents for specific claims here.